US5648254A
(en)
*
|
1988-01-15 |
1997-07-15 |
Zymogenetics, Inc. |
Co-expression in eukaryotic cells
|
US5037743A
(en)
*
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
US6210948B1
(en)
|
1992-06-09 |
2001-04-03 |
The University Of British Columbia |
Expression and secretion of heterologous polypeptides from caulobacter
|
US5563046A
(en)
*
|
1993-08-02 |
1996-10-08 |
Celtrix Pharmaceuticals, Inc. |
Fusion polypeptides and proteins
|
US5914254A
(en)
*
|
1993-08-02 |
1999-06-22 |
Celtrix Pharmaceuticals, Inc. |
Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
|
US6911528B1
(en)
|
1994-12-02 |
2005-06-28 |
The Johns Hopkins University School Of Medicine |
Hedgehog-derived polypeptides
|
US6057091A
(en)
*
|
1994-12-02 |
2000-05-02 |
The Johns Hopkins University School Of Medicine |
Method of identifying compounds affecting hedgehog cholesterol transfer
|
US6281332B1
(en)
*
|
1994-12-02 |
2001-08-28 |
The Johns Hopkins University School Of Medicine |
Hedgehog-derived polypeptides
|
US6214794B1
(en)
|
1994-12-02 |
2001-04-10 |
The Johns Hopkins University School Of Medicine |
Method of using hedgehog polypeptides to regulate neuronal cell growth
|
US6770275B1
(en)
*
|
1996-05-31 |
2004-08-03 |
Akzo Nobel N.V. |
Live attenuated RTC-producing bacteria of the family
|
US5989866A
(en)
|
1996-10-16 |
1999-11-23 |
Zymogenetics, Inc. |
FGF homologs
|
US6036953A
(en)
*
|
1996-11-29 |
2000-03-14 |
The General Hospital Corporation |
Heterologous antigens in live cell V. cholerae strains
|
NZ337958A
(en)
|
1997-03-24 |
2001-03-30 |
Zymogenetics Inc |
Motilin homolog designated zsig33 for treating gastrointestinal cell contractility, secretion of digestive enzymes, gastrointestinal motility, recruitment of digestive enzymes, reflux disease and regulation of nutrient absorption
|
ATE528394T1
(de)
|
1998-06-10 |
2011-10-15 |
Novozymes As |
Neuartige mannasen
|
CZ20011026A3
(cs)
|
1998-09-23 |
2001-08-15 |
Zymogenetics, Inc. |
Izolovaný polynukleotid, expresní vektor, kultivovaná buňka, konstrukt DNA, způsob produkce proteinu, izolovaný polypeptid, způsob produkce protilátky, protilátka a způsob detekce
|
CA2354325C
(en)
|
1998-12-07 |
2011-08-16 |
Zymogenetics, Inc. |
Growth factor homolog zvegf3
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
AU780805B2
(en)
|
1999-01-07 |
2005-04-21 |
Ares Trading S.A. |
Soluble receptor BR43x2 and methods of using
|
CA2261186A1
(en)
|
1999-02-19 |
2000-08-19 |
University Of British Columbia |
Expression and secretion of heterologous polypeptides from freshwater caulobacter
|
CA2366921C
(en)
|
1999-03-09 |
2013-12-17 |
Zymogenetics, Inc. |
Novel cytokine zalpha11 ligand
|
US6664386B1
(en)
|
1999-04-08 |
2003-12-16 |
The Research Foundation Of State University Of New York |
System for efficient secretion of recombinant proteins
|
EP2241623A3
(en)
|
1999-07-07 |
2010-12-01 |
ZymoGenetics, Inc. |
Monoclonal antibody against a human cytokine receptor
|
WO2001044289A2
(en)
*
|
1999-12-17 |
2001-06-21 |
University Of Guelph Office Of The Vice President Of Research |
Modified leukotoxin gene and protein
|
JP2003524415A
(ja)
|
1999-12-23 |
2003-08-19 |
ザイモジェネティクス,インコーポレイティド |
サイトカインzcyto18
|
DE60141234D1
(de)
|
2000-04-05 |
2010-03-18 |
Zymogenetics Inc |
Löslicher Zytokinrezeptor zalpfa11
|
DK1325115T3
(da)
|
2000-06-26 |
2016-11-21 |
Zymogenetics Inc |
Cytokinreceptor zcytor17
|
US7795002B2
(en)
*
|
2000-06-28 |
2010-09-14 |
Glycofi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
DE60128093T2
(de)
|
2000-06-30 |
2007-12-27 |
Zymogenetics, Inc., Seattle |
Interferon-ähnliches protein zcyto21
|
EP1736545A3
(en)
|
2000-08-08 |
2007-03-28 |
ZymoGenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
KR100447530B1
(ko)
*
|
2001-08-14 |
2004-09-08 |
한국과학기술원 |
OmpF를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
|
PT2302063T
(pt)
|
2001-10-15 |
2016-07-28 |
Engeneic Molecular Delivery Pty Ltd |
Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
|
WO2003040313A2
(en)
|
2001-11-05 |
2003-05-15 |
Zymogenetics, Inc |
Il-21 antagonists
|
US7087418B2
(en)
*
|
2001-12-19 |
2006-08-08 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
EP2338910B1
(en)
|
2002-01-18 |
2015-07-08 |
ZymoGenetics, Inc. |
Cytokine receptor Zcytor17 multimers
|
EP1961811B1
(en)
|
2002-01-18 |
2010-08-25 |
ZymoGenetics, Inc. |
Cytokine ligand for the treatment of asthma and airway hyper-responsiveness
|
JP4409962B2
(ja)
|
2002-04-19 |
2010-02-03 |
ザイモジェネティクス,インコーポレイティド |
サイトカイン受容体
|
AU2003243415A1
(en)
|
2002-06-07 |
2003-12-22 |
Zymogenetics, Inc. |
Use of il-21 in cancer and other therapeutic applications
|
DE602004029868D1
(de)
*
|
2003-03-05 |
2010-12-16 |
Chemo Sero Therapeut Res Inst |
Verfahren zur herstellung eines heterologen proteins in e. coli
|
US20040241677A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Lin Jeffrey S |
Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
|
ES2296423B1
(es)
*
|
2003-07-31 |
2009-03-16 |
Consejo Sup. Investig. Cientificas |
Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
|
CN1910200A
(zh)
|
2003-08-07 |
2007-02-07 |
津莫吉尼蒂克斯公司 |
Il-28和il-29的均一化制剂
|
EP2087905A2
(en)
|
2003-08-08 |
2009-08-12 |
Novo Nordisk A/S |
Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
|
EP1673387B1
(en)
|
2003-10-10 |
2010-09-15 |
Novo Nordisk A/S |
Il-21 derivatives
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
NZ547983A
(en)
|
2003-12-09 |
2009-05-31 |
Engeneic Molecular Delivery Pty Ltd |
Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
|
WO2005087810A2
(en)
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
EP1793845A2
(en)
|
2004-07-29 |
2007-06-13 |
ZymoGenetics, Inc. |
Use of il-28 and il-29 to treat cancer
|
EP2166104B1
(en)
|
2004-08-02 |
2013-06-12 |
BASF Plant Science GmbH |
Method for isolation of transcription termination sequences
|
AU2005276145C1
(en)
|
2004-08-26 |
2011-01-06 |
Engeneic Molecular Delivery Pty Ltd |
Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
|
US20060177447A1
(en)
|
2005-02-08 |
2006-08-10 |
Wenfeng Xu |
Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
|
EP3683230A1
(en)
|
2005-05-12 |
2020-07-22 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
WO2006130657A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Bristol-Myers Squibb Company |
Stereoselective reduction process for the preparation of pyrrolotriazine compounds
|
CA2618765A1
(en)
*
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for treating b-cell malignancies using taci-ig fusion molecule
|
AU2006278227B2
(en)
|
2005-08-09 |
2011-10-20 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
UA98462C2
(ru)
*
|
2006-05-15 |
2012-05-25 |
Арес Трейдинг С.А. |
Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
|
LT2712618T
(lt)
|
2006-06-23 |
2017-02-27 |
Engeneic Molecular Delivery Pty Ltd. |
Vaistų, terapinių nukleorūgščių ir funkcinių nukleorūgščių tikslinis įvedimas į žinduolio ląsteles per nepažeistas žuvusias bakterines ląsteles
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
US8318664B2
(en)
|
2007-05-31 |
2012-11-27 |
Alize Pharma Sas |
Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
|
EP2152297B1
(en)
*
|
2007-05-31 |
2015-04-29 |
Alizé Pharma SAS |
Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
|
ES2908934T3
(es)
|
2007-10-04 |
2022-05-04 |
Zymogenetics Inc |
ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
|
DK2602263T3
(da)
|
2007-11-21 |
2019-10-21 |
Roskilde Univ |
Polypeptider omfattende en isbindende aktivitet
|
EP2231702A1
(en)
*
|
2007-12-21 |
2010-09-29 |
Ifxa A/s |
Protease inhibitor
|
EP2245052B1
(en)
*
|
2008-01-25 |
2017-05-24 |
Aarhus Universitet |
Selective exosite inhibition of papp-a activity against igfbp-4
|
SI2274008T1
(sl)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
US8658766B2
(en)
|
2008-06-27 |
2014-02-25 |
Zymogenetics, Inc. |
Soluble hybrid Fcγ receptors and related methods
|
CA2733425A1
(en)
|
2008-08-06 |
2010-02-11 |
Emergent Product Development Uk Limited |
Vaccines against clostridium difficile and methods of use
|
US8647642B2
(en)
|
2008-09-18 |
2014-02-11 |
Aviex Technologies, Llc |
Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
MX2012013899A
(es)
|
2010-06-09 |
2013-03-20 |
Zymogenetics Inc |
Proteinas de fusion vstm3 dimericas y composiciones y metodos relacionados.
|
WO2012106281A2
(en)
|
2011-01-31 |
2012-08-09 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
EP2583975A1
(en)
*
|
2011-10-21 |
2013-04-24 |
Heinrich-Heine-Universität Düsseldorf |
Agents and methods for the expression and secretion of peptides and proteins
|
DK2809795T3
(da)
|
2012-02-01 |
2019-12-16 |
Sgi Dna Inc |
Materialer og fremgangsmåder til syntese af fejlminimerede nukleinsyremolekyler
|
EP3473708B1
(en)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
BR112015004522A2
(pt)
|
2012-09-04 |
2017-11-21 |
Cellectis |
receptor de antígeno quimérico multicadeia e usos destes
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
JP6465794B2
(ja)
*
|
2013-04-25 |
2019-02-06 |
株式会社カネカ |
Fab型抗体の分泌量を増大できるFd鎖遺伝子又はL鎖遺伝子
|
CN109897100A
(zh)
|
2013-05-13 |
2019-06-18 |
瑟勒提斯公司 |
Cd19特异性嵌合抗原受体及其用途
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
EP3082834B1
(en)
|
2013-12-11 |
2020-03-11 |
The General Hospital Corporation DBA Massachusetts |
Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
|
US10239948B2
(en)
|
2013-12-20 |
2019-03-26 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
US9737592B1
(en)
|
2014-02-14 |
2017-08-22 |
David Gordon Bermudes |
Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
|
ES2877606T3
(es)
|
2014-03-19 |
2021-11-17 |
Cellectis |
Método para la fabricación de células T CAR específicas de CD123 para inmunoterapia del cáncer
|
US20170051037A1
(en)
|
2014-05-02 |
2017-02-23 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
MX367787B
(es)
|
2014-07-29 |
2019-09-06 |
Cellectis |
Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
|
WO2016016343A1
(en)
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
EP3189073B1
(en)
|
2014-09-04 |
2019-12-25 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
CN113968915A
(zh)
|
2015-01-26 |
2022-01-25 |
塞勒克提斯公司 |
用于分选/清除工程化的免疫细胞的mAb驱动的嵌合抗原受体系统
|
TWI700298B
(zh)
|
2015-04-13 |
2020-08-01 |
美商輝瑞股份有限公司 |
靶向b細胞成熟抗原之嵌合型抗原受體類
|
US20180112006A1
(en)
|
2015-04-17 |
2018-04-26 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
TW201706300A
(zh)
|
2015-05-20 |
2017-02-16 |
瑟勒提斯公司 |
用於癌症免疫療法之抗-gd3專一性嵌合抗原受體
|
CA2997263C
(en)
|
2015-09-08 |
2022-10-04 |
Theripion, Inc. |
Apoa-1 fusion polypeptides and related compositions and methods
|
EP3405481B1
(en)
|
2016-01-21 |
2023-01-18 |
Pfizer Inc. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
|
SG11201902940RA
(en)
|
2016-10-06 |
2019-05-30 |
Engeneic Molecular Delivery Pty Ltd |
Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
WO2018136163A2
(en)
|
2016-12-09 |
2018-07-26 |
Theripion, Inc. |
Tandem apoa-1 fusion polypeptides
|
US11944643B2
(en)
|
2017-03-31 |
2024-04-02 |
Cellectis Sa |
Universal anti-CD22 chimeric antigen receptor engineered immune cells
|
US20200399343A1
(en)
|
2017-04-19 |
2020-12-24 |
Allogene Therapeutics, Inc. |
Improved t cell compositions and methods
|
SG10202108528QA
(en)
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
EP3645036A1
(en)
|
2017-06-30 |
2020-05-06 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
BR112020001180A2
(pt)
|
2017-07-20 |
2020-09-08 |
Aptevo Research And Development Llc |
proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
WO2019089844A1
(en)
|
2017-11-01 |
2019-05-09 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
AU2018391831B2
(en)
|
2017-12-20 |
2022-08-04 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding CTLA-4 and uses thereof
|
EP3732190A1
(en)
|
2017-12-27 |
2020-11-04 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
US10150801B1
(en)
|
2017-12-27 |
2018-12-11 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
KR20200115596A
(ko)
|
2018-02-01 |
2020-10-07 |
화이자 인코포레이티드 |
Cd70에 특이적인 항체 및 이의 용도
|
EP3746483A1
(en)
|
2018-02-01 |
2020-12-09 |
Pfizer Inc |
Chimeric antigen receptors targeting cd70
|
KR20200128054A
(ko)
|
2018-03-02 |
2020-11-11 |
알로젠 테라퓨틱스 인코포레이티드 |
유도성 키메라 사이토카인 수용체
|
EP3817767A1
(en)
|
2018-07-02 |
2021-05-12 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
EP3880307A1
(en)
|
2018-11-14 |
2021-09-22 |
Fundación Pública Andaluza Progreso Y Salud |
Polynucleotide for safer and more effective immunotherapies
|
US11471497B1
(en)
|
2019-03-13 |
2022-10-18 |
David Gordon Bermudes |
Copper chelation therapeutics
|
CA3150762A1
(en)
|
2019-08-12 |
2021-02-18 |
Aptevo Research And Development Llc |
4-1 bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1 bb, antibodies against ox40
|
EP4021512A1
(en)
|
2019-08-26 |
2022-07-06 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
US10675332B1
(en)
|
2019-08-26 |
2020-06-09 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
EP3882260A1
(en)
*
|
2020-03-18 |
2021-09-22 |
NUMAFERM GmbH |
Fragments of hlya and uses thereof
|
US20230142538A1
(en)
|
2020-03-18 |
2023-05-11 |
Numaferm Gmbh |
Variants of hlya and uses thereof
|
US10973908B1
(en)
|
2020-05-14 |
2021-04-13 |
David Gordon Bermudes |
Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
|
AU2020454690A1
(en)
|
2020-06-22 |
2023-02-02 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and combinations for use in the treatment of cancer
|
US20220023346A1
(en)
|
2020-07-21 |
2022-01-27 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
US20240043868A1
(en)
|
2020-09-21 |
2024-02-08 |
Fundación Pública Andaluza Progreso Y Salud |
Polynucleotide for physiological expression in t-cells
|
EP4255574A1
(en)
|
2020-12-01 |
2023-10-11 |
Aptevo Research and Development LLC |
Heterodimeric psma and cd3-binding bispecific antibodies
|
WO2022140388A1
(en)
|
2020-12-21 |
2022-06-30 |
Allogene Therapeutics, Inc. |
Protease-activating cd45-gate car
|
WO2022165233A1
(en)
|
2021-01-29 |
2022-08-04 |
Allogene Therapeutics, Inc. |
KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
|
WO2022178090A2
(en)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Dnase fusion polypeptides and related compositions and methods
|
CA3208496A1
(en)
|
2021-03-04 |
2022-09-09 |
Michael Thomas Bethune |
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death
|
US20240228553A1
(en)
|
2021-03-18 |
2024-07-11 |
Numaferm Gmbh |
Fusion proteins comprising gg repeat sequences
|
IL308468A
(en)
|
2021-06-15 |
2024-01-01 |
Allogene Therapeutics Inc |
Selective Targeting of Host CD70+ ALLOREACTIVE Cells to Extend Allogeneic CAR T Cell Persistence
|
US20230346934A1
(en)
|
2022-03-29 |
2023-11-02 |
Allogene Therapeutics, Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
WO2024026445A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
EP4339202A1
(en)
|
2022-09-16 |
2024-03-20 |
NUMAFERM GmbH |
Fusion proteins comprising gg repeat sequences ii
|
WO2024148328A2
(en)
|
2023-01-06 |
2024-07-11 |
Aptevo Research And Development Llc |
Bispecific pd-l1 and cd40 binding molecules and uses thereof
|